Literature DB >> 32133823

[Role of JAK2/STAT3 signaling pathway in microglia activation after hypoxic-ischemic brain damage].

Jie Zeng1, Ya-Lin Zhao1, Bo-Wen Deng1, Xiao-Ye Li1, Jie Xu1, Le Wang1, Xiao-Hong Mu1.   

Abstract

Hypoxic-ischemic encephalopathy (HIE) is the leading cause of neonatal death and neurodevelopmental disorders in infants. Part of patients have different degrees of neurological sequelae, such as cerebral palsy, cognitive and motor function development disorders. Hypoxia-ischemia may activate JAK2/STAT3 signaling pathway, which leads to the microglia activation and neuroinflammation. Down-Regulating JAK2/STAT3 signaling pathway can inhibit microglia activation and regulate the inflammatory injury of nervous system. At present, the treatment of hypoxic ischemic encephalopathy is limited, so the study of regulatory mechanism about microglia activation has important value for the treatment of hypoxic-ischemic encephalopathy. This paper summarizes the role of JAK2/STAT3 signaling pathway in microglia activation and analyzes the relationship between them, in order to provide new ideas and strategies for treatment on hypoxic-ischemic encephalopathy.

Entities:  

Keywords:  Hypoxic-ischemic encephalopathy; JAK2/STAT3 signaling pathway; Microglia; Neuroinflammation

Year:  2020        PMID: 32133823     DOI: 10.12200/j.issn.1003-0034.2020.02.0201

Source DB:  PubMed          Journal:  Zhongguo Gu Shang        ISSN: 1003-0034


  2 in total

Review 1.  A Network Pharmacology-Based Identification Study on the Mechanism of Xiao-Xu-Ming Decoction for Cerebral Ischemic Stroke.

Authors:  De-Hui Li; Yi-Fan Su; Chun-Xia Sun; Huan-Fang Fan; Wei-Juan Gao
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-19       Impact factor: 2.629

Review 2.  Multiple Roles of Paeoniflorin in Alzheimer's Disease.

Authors:  Zeyu Meng; Huize Chen; Chujun Deng; Shengxi Meng
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-11       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.